The first three episodes of Ironheart are now streaming on Disney+. The remaining three episodes premiere Tuesday, July 1. Across centuries and cultures, innumerable stories have followed the same ...

Boston Consulting Group finds AAAP on track to shape $25 billion in climate-resilient investments, benefiting nearly 200 million people across Africa. Rotterdam, Sept. 12, 2025 (GLOBE NEWSWIRE) -- The ...

EAST GREENSBORO, N.C. (Sept. 11, 2025) – The fashion merchandising and design program at North Carolina Agricultural and Technical State University will have its turn on the red carpet this week as ...

Captona, a leading energy transition investment firm in North America, today announced the expansion of its signature preferred equity program through its partnership with Scale Microgrids (“Scale”), ...

NEW YORK, September 10, 2025--(BUSINESS WIRE)--Captona, a leading energy transition investment firm in North America, today announced the expansion of its signature preferred equity program through ...

Lorenzo Prieto is a journalism fellow at The Daily Signal. Send an email to Lorenzo. Fox News is shaking up its weekend lineup. Fox News Media President and Executive Editor Jay Wallace announced that ...

From bomber destroyers with nitrous oxide to night fighters with radar and X-4 missiles, the Do 335 spawned a dizzying array of variants. Most never left the drawing board, but test flights proved it ...

SEOUL, Sept. 9 (Yonhap) -- North Korean leader Kim Jong-un has overseen a high-thrust solid-fuel missile engine test using composite carbon fiber material, saying it heralds "a significant change" in ...

SEOUL, South Korea, Sept 9, (AP): North Korea said Tuesday it had conducted the final ground test of a solid-fuel rocket engine for a long-range ballistic missile in its latest advancement toward ...

In latest development of his weapons arsenal, Kim supervised the test of a new solid-fuel rocket engine for North Korea’s ICBMs. Kim Jong Un inspecting a test firing of a rocket launcher at an ...

Takeda ( TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, a potential first-in-class investigational oral orexin ...